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Abstract
Coronavirus disease-19 (COVID-19), a highly contagious viral disease caused 
by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) affects many 
organ systems causing a vast range of clinical manifestations. However, involve-
ment of lungs is the most common manifestation and is the main cause of mortality. 
Detection of viral nucleic acid in the respiratory secretions is the corner stone 
of the diagnosis of COVID-19 infection; however, imaging plays a critical role in 
clinching diagnosis of reverse transcriptase polymerase chain reaction (RT-PCR) 
negative cases and those with atypical presentation. More importantly imaging has 
a pivotal role in the detection of complications and their appropriate management. 
Chest radiography, computed tomography (CT) and magnetic resonance imaging 
(MRI) all have a role in the diagnosis of COVID-19 pneumonia and detection of 
various thoracic complications related to this disease. This chapter comprehensively 
discusses the thoracic manifestations of COVID-19 and the role of imaging in their 
diagnosis and effective management.
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1. Introduction
Coronavirus disease 2019 (COVID-19) first emerged in Wuhan, China in late 
2019 and spread rapidly across the world. COVID-19 has touched vast swathes of 
land affecting 220 countries across the world. The disease has infected an estimated 
57.7 million people and claimed 1.37 million lives as on 23 November, 2020. The 
World Health Organization (WHO) declared COVID-19 a pandemic on 11 March, 
2020 [1].
COVID-19 is a viral disease. The causative agent is a novel enveloped single-
stranded RNA virus belonging to betacoronavirus group and is referred to as severe 
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [2]. SARS-CoV-2 is 
believed to have originated from bats which act as the natural reservoir. The disease 
spreads through human-to-human contact via respiratory route [3]. Coronaviruses 
(CoVs) are classified into three genera of alphacoronavirus, betacoronavirus, and 
gammacoronavirus [4]. CoVs infect animals and humans and cause respiratory, 
gastrointestinal and neurological diseases of various degrees of severity. CoVs 
exhibit the genetic characteristics of mutation and recombination which confers 
them the ability to adapt to new hosts and ecological niches [5].
Respiratory system is the primary target organ of SARS-CoV-2 [6]. However, the 
virus also affects other organ systems including gastrointestinal system, neurologi-
cal system, cardiac and vascular systems [7–11]. Many infected patients do not 
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develop any symptoms. 19–50% patients have been reported to have an asymptom-
atic infection [12]. Asymptomatic patients act as covert transmitters and constitute 
a potential contagious source of SARS-CoV-2 as they unknowingly transmit the 
virus to others [13–17]. However, many patients who are asymptomatic at the time 
of initial diagnosis become symptomatic later and are referred to as pre-symptom-
atic cases [16].
Detection of viral nucleic acid in the respiratory secretions by reverse tran-
scriptase polymerase chain reaction (RT-PCR) is the mainstay of diagnosis [13, 15]. 
RT-PCR has a reported sensitivity of 60–71 percent with a very high specificity [17]. 
However, the performance of RT-PCR is limited by various factors including speci-
men collection, type of specimen, transportation of specimen and the processing 
time which results in many false negative results [18, 19].
Imaging plays a key role in the diagnosis of various manifestations of COVID-19 
and detection of its associated complications. An effective utilization of imaging 
would require a comprehensive understanding and appropriate interpretation of 
the typical and atypical imaging features of the disease. In this chapter we first 
elaborate chest manifestations of COVID-19 and subsequently we discuss the role of 
various chest imaging modalities in their management.
2. Chest manifestations of COVID-19
SARS-CoV-2 which is acquired through the inhalation route primarily targets 
the respiratory system. The symptoms attributable to respiratory system include 
cough, breathlessness, expectoration, sore throat, chest discomfort or pain and 
hemoptysis. Non-specific symptoms include fever, fatigue, and myalgia [20].
SARS-CoV-2 expresses various spike proteins on its outer surface which avidly 
binds to angiotensin converting enzyme-2 (ACE-2). ACE-2 is expressed in alveolar 
pneumocytes and vascular endothelium in abundance. The virus binds to ACE-2 and 
enters into the cell where it replicates and causes cell death with consequent release 
of inflammatory cytokines in profusion which cause damage to the host [21, 22].
The primary manifestation of COVID-19 is pneumonia. The pneumonia is 
usually bilateral and peripheral with a predilection for lung bases. Mild to moderate 
disease constitutes the bulk of cases (80%) and is characterized by constitutional 
symptoms and development of mild pneumonia, whereas severe disease occurs in 
approximately 15% and is generally characterized by more than 50% lung involve-
ment and presents with dyspnea and hypoxia [21]. Critically ill patients constitute 
a small portion (5%) of infections and present with respiratory failure, shock and 
multiorgan dysfunction. Apart from affliction of lungs the bronchial tree is also 
affected by this disease leading to inflammation of bronchial walls [23, 24].
Pulmonary vascular involvement is commonly reported in COVID-19. Frequent 
involvement of pulmonary vessels is a unique feature of COVID-19 which makes 
it different from other viral and bacterial causes of pneumonia [18]. Pulmonary 
embolism frequently occurs in severely ill COVID-19 cases. The underlying 
mechanisms include the triad of Virchow including hypercoagulability induced 
by infection and hypoxia, immobility and vascular endothelial injury [25, 26]. 
However, besides involvement of major pulmonary vessels affection of small pul-
monary vessels has been described as a unique distinguishing feature of COVID-19 
pneumonia [27].
In various autopsy studies of COVID-19 patients small vessel involvement has 
been reported to be the hallmark of COVID-19 pneumonia [28]. Small pulmonary 
vessel thrombosis is commonly found in COVID-19 pneumonia. The putative 
mechanism put forth to explain this includes immunothrombosis [29]. Vascular 
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endothelial injury caused by SARS-CoV-2 upon binding with ACE-2, which is 
expressed abundantly on endothelial cells, leads to severe endothelialitis and 
thrombosis of these small vessels [28–30].
Cardiac manifestations in COVID-19 include arrhythmias, myocarditis, cardio-
myopathy, carcinogenic shock and cardiac arrest and sudden death. Myocarditis 
and cardiomyopathy has been reported in 7% and 7–33% of severely ill COVID-19 
cases, respectively [31, 32]. Myocardial dysfunction evidenced by elevated serum 
troponin levels is associated with poor clinical outcome. Various mechanisms have 
been put forth to explain cardiac injury in COVID-19. COVID-19 can cause direct 
injury to myocardium leading to myocarditis which is a dreaded complication with 
high mortality [32]. Severe infection can induce plaque rupture and coronary artery 
thrombosis leading to myocardial ischemia. Infection associated hypoxia and vaso-
constriction can affect coronary vessels leading to critical myocardial ischemia and 
cardiac dysfunction [33]. Alternately, disseminated intravascular coagulation (DIC) 
induced by severe SARS-CoV-2 infection can precipitate coronary artery thrombo-
sis and cause myocardial infarction [33]. Lastly, stress induced cardiomyopathy can 
also explain myocardial dysfunction in COVID-19 [34].
2.1 Chest X-ray radiography (CXR)
Chest X-ray radiography (CXR) is the preliminary imaging modality employed 
in the initial workup of suspected COVID-19 pneumonia cases [35]. CXR has a 
multitude of unique advantages and limitations. CXR is widely available in almost 
all health facilities including emergency rooms (ER), intensive care units (ICU) and 
wards. Due to the small size of equipment it has the advantage of portability which 
circumvents the transfer of patients away from ICU or wards for performance of 
imaging thereby minimizing the requirements of staff and chances of spread of 
infection [35, 36]. CXR equipment is easy to disinfect. CXR entails a small radiation 
dose to the patient which makes it preferable for children and pregnant patients. 
Owing to these advantages major medical societies across the world have advo-
cated the use of CXR in the workup of individuals suspected of having COVID-19. 
American College of Radiology supported the use of CXR for the evaluation of sus-
pected individuals to facilitate triage and monitoring the course of illness [36, 37].
However, CXR has some major limitations. It has a low sensitivity and specificity 
in the detection of COVID-19 pneumonia. The sensitivity of CXR has been reported 
in the range of 33–69% [38–40]. CXR is insensitive especially in mild cases and 
during the early stages of disease [40]. To address the issue of low sensitivity and 
specificity attempts have been made to take advantage of artificial intelligence by 
developing deep learning algorithms [41, 42]. Deep learning algorithms have been 
found to improve the accuracy of CXR in the detection of COVID-19 pneumonia. 
Most of the patients have a normal CXR during the initial stages of infection, 
however, with the passage of time the positivity rate of CXR increases. It has been 
reported that approximately 80% patients will have a positive CXR at some point 
during the course of hospitalization [43, 44].
A postero-anterior or an antero-posterior CXR is obtained. A slight modifica-
tion of conventional technique has been made by interposing a glass door between 
the patient and film to reduce exposure of radiographer to infection [44]. This 
technique has been found to produce optimal image quality and at the same time 
minimizing the exposure of radiographer to infection.
The typical findings at CXR include consolidations and ground glass opacifica-
tion (GGO) with a peripheral and basal predilection (Figure 1). Peripheral distribu-
tion of pulmonary opacities is one of the specific features of COVID-19 pneumonia 
[45]. Diffuse lung opacification may be seen in patients with severe disease or acute 
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respiratory distress syndrome (ARDS) [46, 47]. Initially the CXR may be normal; 
however, lung opacities may evolve rapidly reaching a peak at around 6–12 days 
[48, 49]. Pleural effusion, pericardial effusion and mediastinal lymphadenopathy 
is seen infrequently in severe cases [44]. The degree of pulmonary opacification on 
CXR has been reported to predict the need for hospitalization or intubation with 
patients having GGO in two lung zones more likely to require hospitalization and 
those with opacification of three or more zones likely to undergo intubation [46]. 
Bilateral lung involvement is seen commonly (73%) whereas, a unilateral lung 
involvement is seen less frequently (<25%) [43, 44]. It is a good clinical practice to 
look beyond lungs when assessing a CXR. Position of tubes (endotracheal tube and 
nasogastric tube) and lines (central venous line) must be assessed on CXR [46].
The two most common radio-opacities of GGO and consolidation are not 
specific to COVID-19 and are seen in many other infectious and non-infectious 
pulmonary pathologies [47, 48]. Non-COVID-19 viral pneumonias like influenza, 
Middle East Respiratory Syndrome (MERS) and other viral pneumonias must be 
included in the differential diagnosis in cases of bilateral pulmonary affection [49]. 
Bacterial pneumonia must be considered in the differential diagnosis particularly 
in cases of unilateral lung involvement [50]. Non-infectious causes of pulmonary 
opacities like pulmonary edema, aspiration, pulmonary hemorrhage, inflammation 
(like pulmonary eosinophilia) and pulmonary vasculitides should be considered in 
the differential diagnosis in appropriate clinical setting [43, 48].
The British Society of Thoracic Imaging (BSTI) guidelines recommend perfor-
mance of CXR in all patients with a oxygen saturation of less than 94% and those 
who do not meet this criterion, CXR should be performed in them when “clinically 
required” [45]. COVID-19 survivors who recover from acute illness require clinico-
radiological follow-up. BSTI guidelines recommend that patients who required ICU 
or high dependency unit (HDU) admission or were managed as in-ward patients 
with severe pneumonia should be assessed virtually at 4-6 weeks post-discharge 
and then face-to-face if needed and subsequently a face-to-face clinical assessment 
along with a CXR must be undertaken at 12 weeks. Patients who did not require 
ICU or HDU admission and were managed as mild–moderate pneumonia should 
undergo a follow-up CXR at 12 weeks [45]. Follow-up CXR are essential to pick any 
residual lung abnormalities sufficiently early to ensure their management to avert 
any long-term fibrotic pulmonary sequelae.
Figure 1. 
CXR in two different RT-PCR confirmed COVID-19 cases showing bilateral ground glass opacification (red 
arrows in A) and multifocal consolidations (red arrows in B) with lower zone predominance.
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2.2 Lung ultrasound (LUS)
Due to its rapidity, easy availability, portability, repeatability and lack of ion-
izing radiation there has been a resurgent use of LUS in COVID-19 pandemic. It has 
been used mostly as a complementary and sometimes as an alternative modality in 
the detection of pulmonary involvement in COVID-19 cases. LUS usage has been 
particularly rewarding in critically ill patients who need a bedside modality which 
could circumvent their transfer out of the intensive care unit (ICU) room [46, 47].
The most common imaging features of LUS in pulmonary involvement in 
COVID-19 include B-lines, thick irregular pleura and subpleural consolidations 
[46]. B-lines are an imaging surrogate of subpleural interlobular septal thickening 
which occurs due to accumulation of fluid in pulmonary interstitium and alveolar 
spaces [48]. B-lines are hyperechoic linear lines, oriented vertically from pleural 
surface into the depths of lung. These lines spread like rays down the ultrasound 
screen and maintain their brightness throughout without fading. B-lines may be 
separate or coalescent. When multiple lines coalesce together they produce what 
is referred to as shining white lung. B-lines should move or slide with respiratory 
excursions [49]. Lack of this sliding movement should alert one to consider the 
possibility of underlying pneumothorax [49].
LUS can be used in emergency room (ER) for prompt detection of pulmonary 
involvement in symptomatic patients suspected of COVID-19 as soon as they arrive 
in the ER. LUS features typical of pulmonary involvement will ensure rapid detec-
tion, prompt isolation and timely treatment of these patients before RT-PCR results 
are available [50].
LUS can prove handy in monitoring the course of illness in inward patients 
by demonstrating the degree of lung involvement. The presence of a few widely 
separated B-lines in limited areas of chest suggests a mild disease whereas multiple 
clumped lines spread in multiple chest areas is indicative of a more severe form of 
disease [50, 51]. Similarly, in ICU setting LUS can help in monitoring the progres-
sion of disease and additionally help in detection of complications like pleural or 
pericardial effusion [51]. LUS can also be used in detection of complications of 
mechanical ventilation like pneumothorax. Ultrasound can also be used in the 
diagnosis of arterial and venous thrombosis, a complication which is frequently 
seen in severe COVID-19 cases [52].
Echocardiography, a specialized form of ultrasound, can aid in detection of 
cardiac complications of COVID-19 like myocarditis, cardiomyopathy, cardiac 
failure, intracardiac thrombosis and major pulmonary artery embolism [53]. 
Echocardiography can be used in this specific disease for the detection of major 
pulmonary embolism and its prognostication [54]. Detection of thrombus in right 
heart, right ventricular outflow tract or main pulmonary artery, akinesis of free 
wall of right ventricle (McConnell’s sign), hypercontractility of right ventricular 
apical wall, dilatation of right ventricle (ventricular diameter of >42 mm at base 
and > 35 mm at mid-cavitary level) and paradoxical motion of interventricular 
septum are specific echocardiographic signs of pulmonary embolism [55, 56]. 
Echocardiography can also detect cardiac dysfunction in myocarditis, myocardial 
ischemia and cardiac failure [56].
2.3 Computed tomography (CT)
CT is a cross-sectional imaging modality which uses x-rays projected through 
multiple angles at the patient to generate an image [22]. The use of CT for the 
diagnosis and screening of COVID-19 has been universally discouraged by various 
radiological societies across the world citing reasons such as lack of specificity of CT 
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for precise diagnosis with overlap seen between COVID-19 pneumonia and other 
viral infections on CT [16, 19]. Secondly, CT entails transfer of patients from wards 
or ICU to CT suite. Finally there is a possibility that CT suites may act as a vector 
of cross infection. The consensus guidelines of American College of Radiology 
(ACR) and European Society of Radiology (ESR) and the European Society of 
Thoracic Imaging (ESTI) do not recommend performance of CT for the diagnosis 
or screening of COVID-19 [16, 22, 31]. CT has thus been reserved for a small subset 
of patients with severe disease, those showing respiratory worsening during illness 
or to monitor the course of disease. However, in some selected circumstances CT 
may also be helpful in patients with milder symptoms who have pre-existing co-
morbidities, such as diabetes mellitus, chronic respiratory disease, obesity, chronic 
kidney disease etc. [57]. Performance of repeat CTs is not routinely indicated 
during recovery. However, a repeat CT may be warranted in cases with suspicion of 
complications likely superadded infection and pulmonary embolism [57].
Notwithstanding the recommendations, CT has been widely performed in 
COVID-19 cases and has been used to support the diagnosis, assess severity, detect 
complications, choose appropriate treatment and monitor response to therapy 
[41]. CT has greatly helped in understanding the natural course of the disease. 
While CXR is considered the first line tool in the initial screening or assessment 
of COVID-19 cases, CT is still employed widely owing to its high sensitivity in the 
detection of pneumonia [43]. In many cases subtle imaging findings which are 
difficult to detect on CXR are readily identifiable on CT.
Typical CT findings include multifocal and bilateral GGOs and or consolida-
tions with peripheral and lower lobe predominance (Figures 2 and 3) [34, 36, 38]. 
Unilateral lung involvement is less common [43]. On CT, GGO is defined as increased 
lung attenuation with preservation of underlying vascular and bronchial structures 
[58]. Consolidation is defined as increased lung attenuation with obscuration of 
underlying bronchial and vascular structures [58]. Other additional features seen 
on CT include crazy paving pattern which is a GGO with superimposed interlobu-
lar septal thickening producing a pavement like appearance [59, 60]. The relative 
frequency of type and distribution of lung lesions varies across different studies. A 
systematic analysis of 34 published studies including 4121 patients revealed bilateral 
lung involvement in 73% [61]. Multilobar lung involvement was seen in 67% patients. 
GGOs were seen in 68%, consolidation in 32% and crazy-paving pattern in 35% 
patients [61]. Additional findings reported were air bronchogram sign (44%), pleural 
thickening (27%), pleural effusion (5%) and lymphadenopathy (5%) [61]. Some 
Figure 2. 
Axial chest CT images at slightly different levels (A, B) in lung window settings of a 56-year-old COVID-19 
patient showing diffuse ground glass opacification in both lungs with a peripheral distribution.
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symptomatic patients may have a normal CT, especially during the early stages of 
disease. Similarly, asymptomatic patients may have an abnormal chest CT [62–64].
CT findings evolve rapidly after symptom onset and reach a peak at around 
6–13 days of illness [63]. There is increase in the extent of lung involvement and 
change in the appearance of pulmonary opacities. GGOs may progress into crazy 
paving pattern or consolidations [64]. Thereafter the findings may remain stable 
for some time and then gradually resorb [65]. However, in some cases there may be 
rapid progression into ARDS [66]. The pulmonary opacities during resolution phase 
start organizing and lead to secondary organizing pneumonia which manifests as 
reverse halo or atoll sign and perilobular opacities [61]. In one study nearly half of 
the patients had residual lung abnormalities consisting of fibrosis 3 months after 
discharge [66]. Other findings observed on CT include segmental or subsegmental 
vascular enlargement (defined as greater than 3 mm diameter) within the lung 
opacities. It has been observed in up to 89% COVID-19 pneumonia [28]. This sign 
of segmental or subsegmental vascular enlargement is a relatively specific sign of 
COVID-19 pneumonia with a diagnostic significance [41]. Presence of vascular 
enlargement sign may help confidently diagnose COVID-19 pneumonia. The under-
lying pathophysiological mechanism for vascular enlargement sign may be related 
to severe vascular inflammation, vasodilatory effect of proinflammatory cytokines 
or small vessel thrombosis [65–67].
Other less common findings observed on CT include reverse halo sign or atoll 
sign, bronchial wall thickening, nodules and halo sign [34]. Reverse halo sign is 
defined as a relatively lucent GGO surrounded by a dense ring of consolidation [51]. 
This finding is typically seen in resorptive stage of the disease. Pleural effusion, 
pericardial effusion and mediastinal lymphadenopathy is seen infrequently par-
ticularly in severe disease [18]. Presence of cavitation or tree in bud nodules are not 
observed in COVID-19 and should arouse suspicion of an alternate diagnosis. CT 
has been reported to have a high sensitivity of around 94% in detecting COVID-19 
[54]. However, the specificity of CT is limited (39%) [68]. The dominant findings 
of GGO and consolidation observed in COVID-19 are seen in many other infectious 
and non-infectious diseases of lung [69, 70]. A comprehensive and detailed clini-
cal information and exposure history is essential during interpretation of CT to 
increase the diagnostic confidence.
To determine the severity of lung inflammation in COVID-19 and help in 
identifying the patients in need of special care, severity scoring systems have been 
devised [71]. Anatomically there are five lobes in two lungs. Each lobe is assessed 
Figure 3. 
Coronal chest CT images at slightly different levels (A, B) in lung window settings of a 61-year-old COVID-19 
patient showing diffuse ground glass opacification in both lungs with both upper and lower lobe involvement.
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individually to determine the degree of pulmonary opacification. Each lobe is 
scored visually from 0 to 5. A score of 0 is assigned if there is no involvement, 
score of 1 for <5% involvement, score 2 for 5–25% involvement, score 3 for 26–50% 
involvement, score 4 for 51–75% involvement and score 5 for >75% involvement. 
The individual scores of all 5 lobes are added to provide a final CT severity score. CT 
severity scores of 1–5 are categorized as mild disease, 6–14 as moderate disease and 
15–25 as severe disease [71, 72]. The disease severity as determined on CT correlates 
with short-term clinical outcome with higher CT severity scores associated with 
worse outcomes [73].
CT imaging features of COVID-19 overlap with many other pulmonary infec-
tions, predominantly viral infections, but it also exhibits some characteristic imag-
ing features which are seen infrequently in other infections [65]. The Radiological 
Society of North America (RSNA) Expert Consensus Statement on Reporting 
proposed a standardized nomenclature and included four categories to determine 
the chances of a pulmonary opacity being COVID-19 [74]. The four categories are 
typical appearance, indeterminate appearance, atypical appearance and negative 
for pneumonia (Table 1) [74]. In March, 2020, the Dutch Radiological Society 
developed a standardized CT based reporting format known as COVID-19 report-
ing and data system (CO-RADS) to ensure uniformity in reporting and to improve 
communication between radiologists and physicians [75]. CO-RADS provides 
a level of suspicion for lung involvement in COVID-19. The degree of suspicion 
increases from CO-RADS category 1 (very low suspicion) to CO-RADS-5 (very 
high suspicion). The two peripheral categories of 0 and 6 are invoked when a CT is 
technically inferior and insufficient for diagnosis or to label a scan in a patient with 
positive RT-PCR result for SARS-CoV-2, respectively (Table 2) [74–76].
2.4 CT pulmonary angiography (CTPA)
CTPA has demonstrated pulmonary embolism in up to 30% of COVID-19 
patients [61]. The location of these emboli has been reported in main pulmonary 
artery (22%), lobar pulmonary artery (34%), segmental pulmonary artery (28%) 
and subsegmental arteries (16%) [77, 78]. In cases with a severe disease with sudden 
respiratory worsening or hemodynamic instability, CTPA is indicated to detect 
pulmonary embolism [77]. Pulmonary embolism is a life-threatening complication 
of COVID-19. However, if diagnosed early and treated appropriately improved out-
comes are observed. CTPA entails administration of a bolus of non-ionic iodinated 
contrast and performance of CT during passage of contrast through the pulmonary 
vascular tree. To ensure optimal timing of scanning a bolus tracking technique is 
used. Pulmonary embolism manifests as a filling defect within a contrast filled 
pulmonary artery [79]. Besides the direct visualization of embolus some indirect 
signs in lungs and heart can be seen. Pulmonary infarction can be seen as a wedge 
shaped peripheral consolidation [80]. Similarly, bowing of interventricular septum, 
dilatation of right ventricle and reflux of contrast into inferior vena cava or hepatic 
veins may be seen and indicates increased pulmonary artery pressure [80, 81].
2.5 CT perfusion angiography
Besides pulmonary macroembolism, involvement of pulmonary microvascu-
lature is a unique feature of COVID-19. Micro vascular dysfunction of pulmonary 
and non-pulmonary organ systems has been widely reported in COVID-19 [66]. It 
is believed that binding of viral spike proteins to ACE-2 on endothelial cells incites 
severe endothelialitis and precipitates microthrombosis of these small vessels. This 
microthrombotic phenomenon also referred to as immunothrombosis has been 
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confirmed by various autopsy studies [15, 23]. This microthrombotic angiopathy 
causes obliteration of vascular bed and results in hypoxemia [29]. Non-contrast CT 
or CTPA cannot detect this condition. The direct visualization of occlusion of micro 
vascular bed is not possible on CTPA as it is beyond the resolution thresholds of 
currently available technology [80]. CT perfusion angiography is an advanced CT 
technology which demonstrates micro vascular thrombosis by detecting pulmonary 
perfusion defects [81]. However, this technology is limited by its availability. It has 
been suggested that CT perfusion angiography may also have a role in COVID-19 
survivors who demonstrate residual respiratory dysfunction by detecting residual 
clot burden [82, 83].
2.6 Magnetic resonance imaging (MRI)
MRI is not recommended for the detection of pulmonary involvement in 
COVID-19. However, in many cases MRI performed for other indications may 
accidentally pick up pulmonary changes consistent with COVID-19 [84]. On MRI, 
Category CT findings
Typical appearance 1. GGOs+/−consolidations or visible intralobular lines (crazy-paving pattern) 
with a bilateral and peripheral distribution.
2. Multifocal GGOs of rounded morphology +/− consolidation or visible intra-
lobular lines (crazy paving pattern)




Absence of typical CT findings and the presence of either of the following:
1. Multifocal, perihilar, diffuse or unilateral GGOs +/− consolidation which lack 
a specific distribution and are non-rounded or non-peripheral
2. Few very small GGOs with a non-rounded and non-peripheral distribution
Atypical appearance Absence of typical or indeterminate findings and the presence of
1. Lobar or segmental consolidation without GGO
2. Discrete small lung nodules (e.g. centrilobular, tree-in-bud appearance)
3. Lung cavitation
4. Smoother interlobular septal thickening with pleural effusion
Negative for 
pneumonia
No CT features of pneumonia (like absence of GGO and consolidation)
Table 1. 
RSNA expert consensus guidelines for reporting CT in patients suspected of COVID-19.
CO-RADS 
category
Level of suspicion CT findings
0 Not interpretable Low quality, technically insufficient scan for assigning a score
1 Very low Normal or non-infectious pathology (like mass)
2 Low Typical for other infection but not COVID-19
3 Equivocal/unsure CT features are ambiguous; compatible with both COVID-19 and 
non-COVID-19 causes of pneumonia
4 High Suspicious for COVID-19
5 Very high Typical for COVID-19
6 RT-PCR proven CT findings of pneumonia with RT-PCR positive for SARS-CoV-2
Table 2. 
COVID-19 reporting and data system (CO-RADS).
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pulmonary parenchymal changes of increased signal intensity on both T1-weighted 
and T2-weighted sequences correspond to GGO and consolidation seen on CXR 
and CT [84, 85]. MRI has found use in the evaluation of cardiac complications 
of COVID-19. MRI has the capability to demonstrate changes of myocarditis or isch-
emia precipitated by COVID-19 infection and also to provide a quantitative measure 
of various cardiac functional indices [85]. In myocarditis, a diffuse increase in myo-
cardial signal intensity on T2-weighted sequence, increase in T1-relaxation values 
on T1-mapping can be seen [84]. Post-contrast studies may reveal late gadolinium 
enhancement in a mid-myocardial or transmural pattern. Cine steady state free 
precession (SSFE) sequences will reveal regional or global wall motion abnormali-
ties with reduced ejection fraction [86].
2.7 Positron emission tomography/computed tomography (PET-CT)
Although PET-CT is not currently indicated in the management of COVID-19 
cases, however, reports of pulmonary findings consistent with COVID-19 have 
emerged when PET-CT was used for other conditions particularly oncology imag-
ing [87]. The lung opacities of GGO and consolidation demonstrate increased 
18-fluorodeoxyglucose (FDG) uptake [88]. Standard uptake values (SUV) of 4.6 to 
12.2 have been reported [88]. Increased FDG uptake has also been demonstrated in 
normal sized mediastinal and hilar nodes in COVID-19. In future, FDG-PET may 
find use in the monitoring of response to treatment and prediction of recovery as 
FDG uptake may help determine the degree of residual inflammation [89, 90].
3. Conclusion
Pulmonary and extra-pulmonary thoracic organ involvement lies at the heart 
of COVID-19 disease manifestation. Chest imaging, although not a substitute for 
microbiological diagnosis of COVID-19, has helped tremendously in understanding 
the natural course of disease and its management. Imaging supports the diagnosis, 
helps in triage, detects complications, guides treatment and is useful in monitor-
ing the response to therapy. A varying combination of CXR, CT, LUS, CTPA and 
MRI performed individually or in different combinations depending on the clinical 
presentation has played a pivotal role in the management of COVID-19 disease.
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